Abstract
A 73-year-old man had undergone right hemicolectomy for advanced colon cancer in May 2006, and he concurrently had multiple liver metastases. After the operation, the patient was given chemotherapy with FOLFIRI. A partial response was achieved for twelve months, and then the liver tumors enlarged. Second-line chemotherapy with FOLFOX was delivered. After several months the liver tumors further enlarged and a new pulmonary lesion appeared with an increased serum CEA level. Therefore, chemotherapy with S-1 (120 mg/day) was started, with 2 weeks' administration followed by a one-week drug-free period. Several months later, the liver tumors and tumor makers decreased. S-1 is expected to be an effective agent for the treatment of advanced colon cancer with liver metastases after FOLFIRI and FOLFOX.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biopsy
-
Camptothecin / analogs & derivatives
-
Camptothecin / therapeutic use
-
Carcinoembryonic Antigen / blood
-
Colonic Neoplasms / blood
-
Colonic Neoplasms / diagnostic imaging
-
Colonic Neoplasms / drug therapy*
-
Drug Combinations
-
Fluorouracil / therapeutic use
-
Humans
-
Leucovorin / therapeutic use
-
Liver Neoplasms / blood
-
Liver Neoplasms / diagnostic imaging
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary
-
Male
-
Organoplatinum Compounds / therapeutic use
-
Oxonic Acid / administration & dosage
-
Oxonic Acid / therapeutic use*
-
Salvage Therapy*
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use*
-
Tomography, X-Ray Computed
Substances
-
Carcinoembryonic Antigen
-
Drug Combinations
-
Organoplatinum Compounds
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid
-
Leucovorin
-
Fluorouracil
-
Camptothecin
Supplementary concepts
-
Folfox protocol
-
IFL protocol